Posted by Michael Wonder on 03 Feb 2021
Cerecor announces fast track designation for CERC-803 for the treatment of leukocyte adhesion deficiency type II
2 February 2021 - Cerecor today announced that the U.S. FDA has granted fast track designation to CERC-803 for the treatment of leukocyte adhesion deficiency type II (LAD-II, also known as SLC35C1-CDG).
The company remains on track to initiate a pivotal trial of CERC-803 in LAD-II in the first half of 2021 and anticipates top line data in the second half of 2021.
